News Releases

Achieved fourth quarter net product revenue of $32.5M representing 52% growth compared to Q4 2021 Achieved full-year net product revenue of $109.3M representing 38% annual growth compared to 2021 on a pro forma basis Ended 2022 with $122.0M in cash, cash equivalents, and short-term investments

Conference call and webcast at 8:30am ET CHICAGO --(BUSINESS WIRE)--Feb. 23, 2023-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies,

CHICAGO --(BUSINESS WIRE)--Jan. 30, 2023-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Food and Drug

CHICAGO --(BUSINESS WIRE)--Jan. 5, 2023-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R.

Company expects to end 2022 with over $120M in cash, cash equivalents, and short-term investments and at the top of its net product revenue guidance of $105M-$110M Company to report Q4 and FY 2022 financial results on or about March 8, 2023 CHICAGO --(BUSINESS WIRE)--Jan.